'Dealing with cancer is devastating enough on its own, but when the drug your doctors have told you that you need costs a ridiculous amount of money, it adds even more stress to an already traumatic situation. Unfortunately, this is the sad reality for the many people who need lomustine, a drug that can be a lifesaver for patients suffering from Hodgkin’s lymphoma and brain tumors.
The drug was sold for years as CeeNU for around $50 a capsule until Bristol-Myers Squib sold it to NextSource. The ruthless startup then raised the price of the drug nine times, bringing its current price to $768 per pill and rebranding it as Gleostine. This is an increase of 1400 percent and far higher than the inflation rate, and it’s an example of pharmaceutical company greed as its worst.
The company’s CEO, Robert DiCrisci, had the audacity to tell the Wall Street Journal that the price was set based on the costs they incurred developing the medication – even though they bought it already fully developed from another company! He also said that the benefits it provides patients is part of the price. In other words, the more desperately the patient needs it, the higher the price they believe they can command for it. Yes, it’s business, but it’s also preying on those in need in the cruelest way possible.'
Read more: Cancer industry drug company ruthlessly raises cancer drug price by 1400% to price gouge patients
Did you like this article?
Thank you for your vote!
13 October 2018
Understanding the medical dictatorship: Medicine has transformed into a business enterprise that is entirely removed from the science of healing
10 October 2018
Mental health checks for ALL pupils: Teachers to assess children as young as four - as Britain appoints world's first Minister for Suicide Prevention
From our advertisers
Trump, The Deep State, & World Events - David Icke On Mainstream Danish Radio - David Icke Dot Connector Videocast
15 hours ago
US won’t impose economic sanctions against Saudis to protect its arms sales to kingdom – analysts
From our advertisers